Michelle Ho

Michelle Ho, Ph.D. joined 5AM Ventures in 2018 as an Analyst and was promoted to Associate in 2020. Dr. Ho joined from Fannin Innovation Studio where she was an Entrepreneurship Fellow leading R&D and BD for two life science startups in Houston, TX. Prior to Fannin, she was a T32 Postdoctoral Fellow in the Department of Gynecologic Oncology at MD Anderson Cancer Center and the Department of Bioengineering at Rice University developing targeted viral vectors for ovarian cancer treatment. Dr. Ho currently serves as an Observer of the Boards of Ensoma, Artiva Biotherapeutics, Cleave Therapeutics and RareCyte. She earned her Ph.D. in Bioengineering from Rice University developing next-generation AAV-based gene therapy vectors in the Suh Lab. She received her B.S. in Bioengineering from the University of California – Berkeley, where she was a Regents’ and Chancellor’s scholar.